In late December 2025, the FDA approved an oral version of Wegovy (semaglutide), giving people prescribed the drug for chronic weight management a pill option for the first time rather than a weekly injection. The approval adds a third semaglutide product to Novo Nordisk’s U.S. lineup, alongside injectable Wegovy and the diabetes pill Rybelsus, in a market where competitors are racing to bring their own oral GLP-1 drugs to market.
What Was Approved
The FDA cleared a once-daily oral tablet of semaglutide, marketed under the Wegovy name, for chronic weight management in adults with obesity or overweight plus at least one weight-related condition — the same population covered by injectable Wegovy. Approved dosing scales up to a 25 mg maintenance dose, well above the 14 mg ceiling on Rybelsus, which remains approved only for type 2 diabetes. Novo Nordisk has said the starting 1.5 mg dose became available in U.S. pharmacies in early January 2026.
What the OASIS-4 Trial Showed
The approval rested primarily on OASIS-4, a placebo-controlled Phase 3 trial. Patients who adhered to the oral regimen lost an average of 16.6% of body weight, compared with 2.7% among those on placebo. Novo Nordisk has described these results as consistent with STEP 1, the pivotal trial that originally supported injectable Wegovy’s approval, and an indirect comparison presented at ObesityWeek 2025 suggested the oral and injectable formulations offer broadly comparable efficacy — though the two have not been tested head-to-head within a single trial.
How It Differs From Rybelsus and Injectable Wegovy
Rybelsus has been available since 2019, but only for type 2 diabetes, at doses well below what’s used for weight management. Oral Wegovy is a higher-dose formulation of the same molecule, approved specifically for weight loss. Compared with injectable Wegovy, the pill removes the need for a weekly injection and the cold-chain handling that comes with an injectable pen, though, like other oral peptide drugs, it still requires a specific dosing routine — taken on an empty stomach, with a wait before eating or drinking — to be absorbed reliably.
How It Compares to Competing Oral GLP-1s
Novo Nordisk isn’t the only company chasing an oral option. Eli Lilly’s orforglipron, covered elsewhere on this site, was approved as the first oral GLP-1 pill without food-or-water restrictions, but its highest-dose Phase 3 results (12.4% average weight loss at 72 weeks) trailed the OASIS-4 numbers for oral Wegovy. Cross-trial comparisons like this one are inherently limited, since the trials enrolled different populations on different timelines, so the more meaningful comparison will come as real-world data on both drugs accumulates.
Cost and Access
Novo Nordisk has priced the starting dose at $149 a month through its direct-to-consumer NovoCare pharmacy channel, a figure the company has positioned against the injectable version’s list price. Actual out-of-pocket costs still depend heavily on insurance coverage, which, as this site’s guide to GLP-1 insurance policy explains, remains inconsistent across payers for weight-management indications specifically.
Talk to a Doctor
Like injectable Wegovy, the oral version carries the same class-wide warnings around thyroid C-cell tumors, pancreatitis, and gastrointestinal side effects. Anyone considering a switch between formulations, or starting semaglutide for the first time, should discuss dosing, side effects, and their own medical history with a prescriber rather than treating this article as guidance for an individual decision.